Dr. Lin Shen
Claim this profileBeijing Cancer Hospital
About Lin Shen
Education:
- Obtained MD (Doctor of Medicine) from Peking University Health Science Center in 2005.
Experience:
- Completed residency in Oncology at Beijing Cancer Hospital.
- Serves as an attending physician at Beijing Cancer Hospital, a leading institution in cancer care in China.
Area of expertise
Solid Tumors
Lin Shen has run 23 trials for Solid Tumors. Some of their research focus areas include:
Stomach Cancer
Lin Shen has run 12 trials for Stomach Cancer. Some of their research focus areas include:
Clinical Trials Lin Shen is currently running
TSN1611
for Cancer
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
Recruiting
1 award
Phase 1 & 2
3 criteria
CS5001
for Advanced Cancers
This trial is testing a new drug called CS5001 to see if it is safe and effective for patients with advanced blood-related and solid cancers. The drug aims to attack and stop the growth of cancer cells.
Recruiting
1 award
Phase 1
10 criteria
More about Lin Shen
Clinical Trial Related
3 years of experience running clinical trials · Led 54 trials as a Principal Investigator · 17 Active Clinical Trials
Treatments Lin Shen has experience with
- Oxaliplatin
- Cisplatin
- Trastuzumab
- Pembrolizumab
- Sunitinib
- Capecitabine
Breakdown of trials Lin Shen has run
Solid Tumors
Stomach Cancer
Colorectal Cancer
Pancreatic Cancer
Esophageal Cancer
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- CBP-1019 for Advanced Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lin Shen specialize in?
Lin Shen focuses on Solid Tumors and Stomach Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Lin Shen currently recruiting for clinical trials?
Yes, Lin Shen is currently recruiting for 8 clinical trials in Beijing Beijing. If you're interested in participating, you should apply.
Are there any treatments that Lin Shen has studied deeply?
Yes, Lin Shen has studied treatments such as Oxaliplatin, Cisplatin, Trastuzumab.
What is the best way to schedule an appointment with Lin Shen?
Apply for one of the trials that Lin Shen is conducting.
What is the office address of Lin Shen?
The office of Lin Shen is located at: Beijing Cancer Hospital, Beijing, Beijing 100142 China. This is the address for their practice at the Beijing Cancer Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.